Abstract
Background
Although obscure gastrointestinal bleeding cannot be detected by colonoscopy or upper endoscopy, wireless video capsule endoscopy (VCE) is capable of imaging it. Few data are available on medical therapy for patients with nonsteroidal anti-inflammatory drug (NSAID)-induced small-intestinal mucosal injuries. The aim of this study was to compare prevention by rebamipide and placebo of NSAID-induced smallintestinal injury in healthy subjects.
Methods
Ten healthy subjects who provided written informed consent were enrolled. Rebamipide or placebo plus diclofenac was administered with omeprazole for 7 days, and for an additional 7-day period with treatments reversed in the same subjects, with a 4-week washout period between treatments. VCE of the small intestine was performed four times, before and after each of the two study periods.
Results
The number of subjects with small-intestinal mucosal injuries was higher in the placebo group (8/10) than in the rebamipide group (2/10) (P = 0.023). Two cases of ulcer and one of bleeding were observed in the placebo group, while no ulcer or bleeding was observed in the rebamipide group.
Conclusions
Rebamipide had significantly higher efficacy than placebo in preventing NSAID-induced small-intestinal mucosal injury.
Similar content being viewed by others
References
Zuckerman GR, Prakash C, Askin MP, Lewis BS. Lewis BS. AGA technical review on the evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology 2000;118:201–221.
MacKenzie JF. Push enteroscopy. Gastrointest Endosc Clin North Am 1999;1:29–36.
Seensalu R. The sonde examination. Gastrointest Endosc Clin North Am 1999;1:37–59.
Iddan G, Meron G, Glukhovsky A, Swain P. Wireless capsule endoscopy. Nature 2000;405:417.
Gong F, Swain P, Mills T. Wireless endoscopy. Gastrointest Endosc 2000;51:725–729.
Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005;3:55–59.
Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133–141.
Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, et al. COX-1 and 2, intestinal integrity and pathogenesis of NSAID-enteropathy in mice. Gastroenterology 2002;122:1913–1923.
Whittle BJR. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol 2004;500:427–439.
Bjarnason I, Williams P, So A, Zanelli GD, Levi AJ, Gumpel JM, et al. Intestinal permeability and inflammation in rheumatoid arthritis; effects of non-steroidal anti-inflammatory drugs. Lancet 1984;ii:1171–1174.
Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ. Misoprostol reduces indomethacin induced changes in human small intestinal permeability. Dig Dis Sci 1989;34:407–411.
Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ. Metronidazole reduces inflammation and blood loss in NSAID enteropathy. Gut 1992;33:1204–1208.
Hayllar J, Smith T, Macpherson A, Price AB, Gumpel M, Bjarnason I. Nonsteroidal anti-inflammatory drug induced small intestinal inflammation and blood loss: effect of sulphasalazine and other disease modifying drugs. Arthritis Rheum 1994;37:1146–1150.
Yamasaki K. Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats. Jpn J Pharmacol 1989;49:441–448.
Arakawa T. Rebamipide, a novel prostaglandin-inducer, accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer: comparison with cimetidine. Dig Dis Sci 1995;40:2469–2472.
Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol 2001;16:1112–1119.
Naito Y, Yoshikawa T, Tanigawa T, Sakurai K, Yamasaki K, Uchida M, et al. Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 1995;18:117–123.
Laharie D, Ménard S, Asencio C, Vidal-Martinez T, Rullier A, Zerbib F, et al. Effect of rebamipide on the colonic barrier in interleukin-10-deficient mice. Dig Dis Sci 2007;52:84–92.
Zea-Iriarte WL, Makiyama K, Goto S, Murase K, Urata Y, Sekine I, et al. Impairment of antioxidants in colonic epithelial cells isolated from trinitrobenzene Sulphonic acid-induced colitis rats. Scand J Gastroenterol 1996;31:985–992.
Niwa Y, Nakamura M, Ohmiya N, Itoh A, Hirooka Y, Goto H. Ileal cancer and erosions in the small intestine revealed by capsule endoscopy. Endoscopy 2007: Feb 7 [Epub ahead of print].
Sidhu R, Sanders DS, McAlindon ME, Kapur K. Capsule endoscopy for the evaluation of nonsteroidal anti-inflammatory drug-induced enteropathy: United Kingdom pilot data. Gastrointest Endosc 2006;64:1035.
Maiden L, Thjodleifsson B, Seigal A, Bjarnason II, Scott D, Birgisson S, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007;5:1040–1045.
Naito Y, Yoshikawa T, Iinuma S, Yagi N, Matsuyama K, Boku Y, et al. Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebocontrolled study. Dig Dis Sci 1998;43:83–89S.
Park S-H, Cho C-S, Lee O-Y, Jun J-B, Lin S-R, Zhou L-Y, et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM study. J Clin Biochem Nutr 2007;40:148–155.
Yamao J, Kikuchi E, Matsumoto M, Nakayama M, Ann T, Kojima H, et al. Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE—famotidine or rebamipide in comparison by endoscopy). J Gastroenterol 2006;41:1178–1185.
Furuta R, Ando T, Watanabe O, Maeda O, Ishiguro K, Ina K, et al. Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis. J Gastroenterol Hepatol 2007;22:261–267.
Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989;34:407–411.
Davies GR, Wilkie ME, Rampton DS. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sci 1993;38:417–425.
Kuroda M, Yoshida N, Ichikawa H, Takagi T, Okuda T, Naito Y, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med 2006;17:89–93.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Niwa, Y., Nakamura, M., Ohmiya, N. et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol 43, 270–276 (2008). https://doi.org/10.1007/s00535-007-2155-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-007-2155-4